- QuidelOrtho recently announced a long-term supply agreement with Lifotronic Technology to broaden its immunoassay analyzer platforms and add over 70 assays, including more than 25 not currently offered on its VITROS system, across select markets outside the United States.
- This collaboration could materially reshape QuidelOrtho’s international diagnostics offering by helping it compete for full‑menu tenders and better serve both small and high‑throughput laboratories.
- Next, we’ll examine how gaining access to additional high‑throughput immunoassay platforms might influence QuidelOrtho’s existing investment narrative.
Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
QuidelOrtho Investment Narrative Recap
To own QuidelOrtho, you have to believe that its broad diagnostics portfolio and international expansion can eventually offset shrinking COVID testing and recent losses, while management executes a complex turnaround. The Lifotronic agreement appears helpful for the near term by strengthening the immunoassay offering in key ex US markets, but it does not change the core near term catalyst of stabilizing non COVID revenues or the key risk that ongoing losses and product discontinuations could persist.
Among recent developments, the planned retirement of long serving CFO Joseph Busky stands out, given QuidelOrtho’s 2025 net loss of US$1,131.8 million and guidance for continued unprofitability. A smooth finance leadership transition will matter as the company integrates new partnerships like Lifotronic, manages debt, and works to translate incremental international growth opportunities into more durable margins and improved earnings quality.
Yet beneath the appeal of a larger test menu, investors should be aware that...
Read the full narrative on QuidelOrtho (it's free!)
QuidelOrtho's narrative projects $3.0 billion revenue and $17.2 million earnings by 2028.
Uncover how QuidelOrtho's forecasts yield a $34.67 fair value, a 53% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming only about 2.5 percent annual revenue growth to roughly US$2.9 billion and continued losses, so compared with the baseline view they paint a much tougher path if government price controls and aggressive local competitors blunt the benefits of new partnerships like Lifotronic, reminding you that reasonable people can look at the same numbers and reach very different conclusions.
Explore 2 other fair value estimates on QuidelOrtho - why the stock might be worth just $34.67!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.
Interested In Other Possibilities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
- Find 54 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com